These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 17986149)
1. Gangliosides as targets for autoimmune injury to the nervous system. Willison HJ J Neurochem; 2007 Nov; 103 Suppl 1():143-9. PubMed ID: 17986149 [TBL] [Abstract][Full Text] [Related]
2. The immunobiology of Guillain-Barré syndromes. Willison HJ J Peripher Nerv Syst; 2005 Jun; 10(2):94-112. PubMed ID: 15958123 [TBL] [Abstract][Full Text] [Related]
3. Anti-ganglioside antibodies and the presynaptic motor nerve terminal. Willison HJ; Plomp JJ Ann N Y Acad Sci; 2008; 1132():114-23. PubMed ID: 18567860 [TBL] [Abstract][Full Text] [Related]
5. The Guillain-Barré syndrome: a true case of molecular mimicry. Ang CW; Jacobs BC; Laman JD Trends Immunol; 2004 Feb; 25(2):61-6. PubMed ID: 15102364 [TBL] [Abstract][Full Text] [Related]
6. Carbohydrate mimicry: a new paradigm of autoimmune diseases. Yuki N Curr Opin Immunol; 2005 Dec; 17(6):577-82. PubMed ID: 16229995 [TBL] [Abstract][Full Text] [Related]
7. Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a. Tatsumoto M; Koga M; Gilbert M; Odaka M; Hirata K; Kuwabara S; Yuki N J Neuroimmunol; 2006 Aug; 177(1-2):201-8. PubMed ID: 16844234 [TBL] [Abstract][Full Text] [Related]
8. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Yuki N; Susuki K; Koga M; Nishimoto Y; Odaka M; Hirata K; Taguchi K; Miyatake T; Furukawa K; Kobata T; Yamada M Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11404-9. PubMed ID: 15277677 [TBL] [Abstract][Full Text] [Related]
9. [Clinical features of neuropathies in a group of patients associated with anti-GalNAc-GD1a antibody]. Tatsumoto M; Odaka M; Koga M; Hirata K; Yuki N Rinsho Shinkeigaku; 2004 Aug; 44(8):508-12. PubMed ID: 15471085 [TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome: update on immunobiology and treatment. Kaida K; Kusunoki S Expert Rev Neurother; 2009 Sep; 9(9):1307-19. PubMed ID: 19769446 [TBL] [Abstract][Full Text] [Related]
11. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Zhang G; Lopez PH; Li CY; Mehta NR; Griffin JW; Schnaar RL; Sheikh KA Brain; 2004 May; 127(Pt 5):1085-100. PubMed ID: 14985267 [TBL] [Abstract][Full Text] [Related]
12. Anti-glycolipid antibodies in the diagnosis of autoimmune neuropathies. Willison HJ Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S16-20. PubMed ID: 12690656 [TBL] [Abstract][Full Text] [Related]
13. Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach. Asthana P; Vong JS; Kumar G; Chang RC; Zhang G; Sheikh KA; Ma CH Mol Neurobiol; 2016 Sep; 53(7):4981-91. PubMed ID: 26374552 [TBL] [Abstract][Full Text] [Related]
14. Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome. van Sorge NM; van der Pol WL; Jansen MD; van den Berg LH Autoimmun Rev; 2004 Feb; 3(2):61-8. PubMed ID: 15003189 [TBL] [Abstract][Full Text] [Related]
15. A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies. Uncini A Exp Neurol; 2012 Jun; 235(2):513-6. PubMed ID: 22507308 [TBL] [Abstract][Full Text] [Related]